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Oral capecitabine is a highly active, well-tolerated and convenient treatment for breast and colorectal cancer. This trial assessed the
efficacy and safety of single-agent capecitabine in patients with previously treated ovarian cancer. A total of 29 patients with platinum-
pretreated relapsed ovarian cancer were enrolled in this prospective, open-label, single-centre, phase II study. Patients received oral
capecitabine 1250mgm
 2 twice daily on days 1–14 of a 21-day cycle. Tumour response was evaluated using serum CA125. Out of
29 enrolled patients, 28 were evaluable, and a response was observed in eight patients (29%, 95% confidence interval (CI), 13–49%).
Median progression-free and overall survivals were 3.7 (95% CI, 2.8–4.6) and 8.0 (95% CI, 4.1–11.8) months, respectively. After 6
months of treatment, 28% (95% CI, 13–48%) of patients remained progression-free and 62% (95% CI, 42–79%) were still alive. The
most common clinical adverse events were hand–foot syndrome (HFS), nausea and diarrhoea. Grade 3 HFS occurred in 14% of
patients, grade 3 vomiting in 10%. Efficacy and safety of capecitabine compare favourably with other monotherapies in platinum-
refractory epithelial ovarian cancer. The convenience and improved safety profile of capecitabine compared with intravenous.
regimens make it an ideal agent for administration in the outpatient setting.
British Journal of Cancer (2003) 89, 1843–1848. doi:10.1038/sj.bjc.6601381 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: capecitabine; fluoropyrimidine; ovarian cancer; quality of life
                                         
Despite the development of more effective chemotherapy and the
refinement of surgical techniques, ovarian cancer remains the
number one cause of death from gynaecological cancer in the
Western world (Jemal et al, 2002). The treatment of ovarian cancer
has become characterised by high response rates to first-line
therapies, followed by relapse in the majority of patients and
generally poor results in the second-line setting. Platinum-based
regimens have consistently achieved response rates of around 70%
when used as first-line therapy (Thigpen, 2000), but the high rate
of relapse has meant that 5-year survival in patients with ovarian
cancer remains around 50% (Ozols, 2002).
The most important predictor of response to second-line
treatment is the time from initial chemotherapy, known as the
treatment-free interval. This has been best characterised for
platinum (Blackledge et al, 1989; Gore et al, 1990; Markman et al,
1991), where a spectrum of sensitivity to rechallenge with platinum
agents has been observed. Patients relapsing more than 24 months
after initial platinum therapy have a 60% or greater chance of a
further response, whereas patients relapsing within 6 months may
have as little as a 10–15% chance of a further response with these
agents. Although several agents, including anthracyclines, taxanes,
gemcitabine and topotecan, have been used in patients with
platinum-pretreated ovarian cancer, there is a general paucity of
randomised trial data in this setting (Markman, 2002).
Many patients with advanced ovarian cancer have disease that
cannot be adequately visualised using CT scans or ultrasonogra-
phy, and CA125 response has been shown to be an effective and
satisfactory way of evaluating biological activity. An analysis of 19
clinical trials evaluating 14 different drugs in relapsed ovarian
cancer demonstrated that definitions of response, based on both a
50% and 75% decrease of CA125 concentrations, accurately
predicted which drugs were active and justified further investiga-
tion (Rustin et al, 2000). In these studies, the CA125 and clinical
response criteria were concordant in 20 of the 25 treatment groups,
including docetaxel, gemcitabine, oxaliplatin, paclitaxel and
topotecan. Response rates according to CA125 are slightly higher
than standard clinical response rates, but based on the analysis
above, Rustin et al (2000) concluded that response rates were so
similar that either standard or CA125 response criteria could be
used in clinical trials.
The goal of second-line therapy in ovarian cancer is essentially
palliative, and therefore factors such as patient convenience and
comfort, toxicity profile and cost are primary concerns in drug
selection in this setting (Gadducci et al, 2001). Accordingly, health-
related quality of life (QOL) assessment has become increasingly
important in gynaecological oncology (Pignata et al, 2001). For
this reason, effective treatment options that do not compromise
tolerability or patients’ convenience are desirable.
5-Fluorouracil (5-FU) modulated by folinic acid has shown
promise in the treatment of patients with platinum-refractory
ovarian cancer. In a study evaluating bolus 5-FU administered at a
dose of 370mgm
 2 with folinic acid 200mgm
 2 for 5 consecutive
days every 4–5 weeks, a 17% response rate was seen and the
regimen was generally well tolerated (Look et al, 1995). The highly
active, oral fluoropyrimidine capecitabine (Xeloda
s: F Hoffmann-
La Roche, Basel, Switzerland) was rationally developed to deliver
5-FU preferentially to tumours by exploiting the high concentra-
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ltions of thymidine phosphorylase in tumour tissue. Capecitabine is
absorbed through the intestinal mucosa as an intact molecule and
is converted to 5-FU via a three-step enzymatic activation cascade,
involving thymidine phosphorylase and cytidine deaminase, both
of which are upregulated in ovarian cancer cells (Miwa et al, 1998).
Capecitabine showed promise in phase I trials that included
patients with ovarian cancer (Budman et al, 1998; Mackean et al,
1998), and a wide-ranging clinical trial programme continues to
examine its efficacy and safety in a number of malignancies.
Following impressive results in phase III trials, capecitabine has
become established as an effective and well-tolerated first-line
therapy for patients with advanced colorectal cancer (Hoff et al,
2001; Van Cutsem et al, 2001; Twelves, 2002). Based on results
from extensive clinical trials in more than 700 patients with
metastatic breast cancer (MBC) (Blum et al, 1999; Blum et al, 2001;
Reichardt et al, 2001; Fumoleau et al, 2002; Miller et al, 2002),
capecitabine monotherapy is considered by many to be the
reference treatment in taxane-pretreated MBC and is the only
agent to have received worldwide regulatory approval in this
setting. In addition, the combination of capecitabine plus
docetaxel 75mgm
 2 has been shown to significantly improve
survival in anthracycline-pretreated patients with MBC, with a
median 3-month survival benefit compared with docetaxel
100mgm
 2 alone (O’Shaughnessy et al, 2002). This combination
has consequently received regulatory approval in more than 50
countries as therapy for anthracycline-pretreated patients with
MBC.
Recent studies have demonstrated a strong patient preference
for oral rather than intravenous (i.v.) therapies, with two
independent studies showing a preference for oral therapy in 84
and 89% of patients, as long as efficacy is not sacrificed (Liu et al,
1997; Borner et al, 2002). A third study demonstrated that home-
based therapy results in significant improvements in QOL
compared with hospital-based therapy in the palliative setting
(Payne, 1992).
We conducted an open-label, phase II trial of single-agent
capecitabine in patients with previously treated ovarian cancer to
assess the efficacy and safety of this regimen, and to determine its
impact on QOL.
PATIENTS AND METHODS
Study design
This prospective, open-label, single-centre, phase II study exam-
ined the efficacy and safety of capecitabine in women with
platinum-pretreated epithelial ovarian cancer. The study was
approved by the local ethics committee (West Ethics Committee,
North Glasgow Trust, UK) and run in accordance with the
Declaration of Helsinki. All patients provided signed, informed
consent before study entry.
Eligibility criteria
Women with platinum-pretreated epithelial ovarian cancer that
had relapsed within 12 months of the last course of chemotherapy
were eligible for the study. Patients were required to have
previously received a platinum agent, although not necessarily as
part of the most recent treatment regimen. A maximum of three
previous lines of chemotherapy was allowed. Patients were
required to have measurable disease, defined as serum
CA125X100kUl
 1, with documented CA125 progression (Rustin
et al, 1996). Other eligibility criteria included ageX18 years,
performance status o3 (ECOG scale), life expectancyX18 weeks
and adequate bone marrow (neutrophils 42 10
9l
 1, platelets
475 10
9l
 1), liver (AST and/or ALT o5 times upper limit of
normal) and renal (serum creatinine o1.5 times upper limit of
normal) function. Patients with clinically significant cardiac
disease or who had experienced myocardial infarction within the
previous 12 months were excluded, as were those who had
evidence of CNS metastases, or known sensitivity or prior severe
reaction to 5-FU.
Treatment schedule
The treatment schedule consisted of oral capecitabine 1250mgm
 2
administered twice daily for 14 days, followed by a 7-day rest
period. Treatment was administered orally within 30min of
breakfast and dinner, and swallowed with approximately 200ml
of water. The cycle was repeated every 21 days and all patients
received at least two cycles of study treatment. Dose interruption
and reduction were used to manage adverse events and the scheme
is summarised in Table 1. Patients responding or stable after 18
weeks could continue on treatment indefinitely at the investiga-
tor’s discretion, until disease progression or intolerable toxicity.
Assessment of response
The primary end points of this phase II study were response rate
and duration of response, determined using weekly measurements
of serum CA125. Response was defined as fulfilling either of the
following criteria: (A) if there was a 50% decrease in serum CA125
from two previous, consistently elevated samples; or (B) if there
has been a serial decrease in CA125 concentrations of more than
75% over three samples (Rustin et al, 1996). In both these
definitions, the final sample must have been taken at least 28 days
after the previous sample. In patients with clinically or radi-
ologically evaluable disease at baseline, specific tumour assess-
ments including CT scans and/or measurements were carried out
at 6-weekly intervals and response was defined by modified
Southwest Oncology Group (SWOG) response criteria.
Safety assessments were performed at each clinic visit. Adverse
events were monitored throughout the study period and for 28
days after stopping study treatment. Patients were advised to
Table 1 Capecitabine dose modification scheme
Grade 2 Grade 3 Grade 4
First appearance Interrupt treatment until resolved to grade
0–1, then continue at same dose with
prophylaxis
a where possible
Interrupt treatment until resolved to grade
0–1, then continue at 75% dose, with
prophylaxis
a where possible
Interrupt treatment unless the investigator
considers it to be in the best interests of the
patient to continue at 50% dose once
toxicity has resolved to grade 0–1
Second appearance Interrupt treatment until resolved to grade
0–1, then continue at 75% dose
Interrupt treatment until resolved to grade
0–1, then continue at 50% dose
Third appearance Interrupt treatment until resolved to grade
0–1, then continue at 50% dose
Discontinue treatment – off study
Fourth appearance Discontinue treatment – off study
aFor example, loperamide for diarrhoea, emollients and pyridoxine for hand–foot syndrome.
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lcontact their oncology team if they experienced symptoms
possibly related to treatment. Adverse events were graded
according to National Cancer Institute Common Toxicity
Criteria (NCI CTC). Haematological assessments, including
full blood count and differential, were carried out at each
patient visit. Liver and renal functions were assessed on a
3-weekly basis and parameters included AST/ALT, alkaline
phosphatase, serum protein, total bilirubin, urea and electrolytes
and serum creatinine. Chest X-rays were performed if clinically
indicated.
The impact of therapy or disease progression/evolution on
patients’ well-being was assessed by self-administration of the
European Organisation for Research and Treatment of Cancer
(EORTC) Quality of Life questionnaires (QLQ-C30 version 3 and
QLQ-C24 version 1). Patients were required to complete these
questionnaires at baseline and prior to each 3-weekly cycle.
Statistical methods
A two-stage Gehan design was employed with a target response
rate of 20%, power set at 95% and a precision of 10%. This design
requires a maximum of 25 evaluable patients. Overall survival and
progression-free survival were estimated using the Kaplan–Meier
method. All times were measured from the start of treatment.
RESULTS
Recruitment began in May 1999, and 29 patients had been entered
by study close (extra patients were recruited to allow for
unevaluables) in November 2001. By February 2002, median
follow-up duration from the start of treatment for living patients
was 16 months (range 8–28 months). Patients had received a
median of two lines of chemotherapy, 13 (45%) had undergone
surgery prior to study enrolment and three had received prior
radiotherapy. Patient characteristics and treatment histories are
summarised in Table 2. No patients had previously received 5-FU-
based chemotherapy. Median CA125 at study entry was 884kUl
 1
(range 153–9750), and the median platinum-free interval was 8
months (range 2–47).
A total of 121 cycles of capecitabine were administered, with
patients receiving a median of four (range 1–9) cycles. Seven
patients required dose reductions, of whom two required a second
dose reduction. Six cycles were delayed because of treatment-
related adverse events. Four patients omitted capecitabine doses
on several days because of treatment-related adverse events (two
grade 3 hand–foot syndrome (HFS), one grade 3 diarrhoea, one
grade 3 vomiting). Treatment-related adverse events occurred
early in the treatment course and were readily managed with dose
interruption and, if necessary, dose reduction. Two patients
withdrew from treatment because of toxicity (grade 3 HFS in both
cases).
Responses and survival
The CA125 response was observed in eight of 28 evaluable patients
giving a response rate of 29% (95% confidence interval (CI), 13–
49%). One patient was unevaluable because of insufficient CA125
concentrations. There were no significant differences in response
rates according to platinum-free interval o6o r 46 months (44 vs
21%, P¼0.47) or treatment-free interval o6o r46 months (24 vs
33%), but the small patient numbers in this comparison make
identification of small differences difficult.
Typical responder profiles for two patients are illustrated in
Figure 1. Median progression-free and overall survival durations
were 3.7 (95% CI, 2.8–4.6) months and 8.0 (95% CI, 4.1–11.8)
months, respectively (Figures 2 and 3). After 6 months of
treatment, 28% (95% CI, 13–48%) of patients remained progres-
sion-free and 62% (95% CI, 42–79%) were still alive.
Drainage of ascites can affect the CA125 dynamics, although
there are no robust guidelines about how to interpret this. It has
been suggested that values taken within 4 weeks of this procedure
should be discounted (GJS Rustin, personal communication). Six
patients in the study had ascites drained either during the
treatment period, or up to 3 weeks before. If the CA125 values
collected for these patients within 4 weeks of drainage are ignored,
response rate is reduced to 27%, as two patients would be unable
to be classified as responders from the remaining values.
In total, 14 patients had measurable disease at baseline, and a
complete radiological response was observed in one patient, giving
a clinical overall response rate of 7%. This patient was not
evaluable for the CA125 response despite having a sustained
450% fall in this marker, because one of her values was 410%
higher than the previous value during the study. Disease
stabilisation occurred in a further five patients, resulting in an
overall rate of disease control of 43% according to radiological
assessment.
Toxicity summary
All 29 patients were evaluable for safety (Table 3). Capecitabine
was very well tolerated, with the most common clinical adverse
events being HFS, nausea and diarrhoea. The only grade 3 adverse
event occurring in more than 10% of patients was grade 3 HFS, a
non-life-threatening side effect. This occurred in four patients
(14%), and grade 3 vomiting occurred in three patients (10%).
Myelosuppression and alopecia were rare, with only one patient
Table 2 Patient characteristics and treatment histories
No. of patients 29
Median age: range (years) 57 (38–78)
Performance status
0 8 (28%)
1 17 (59%)
2 1 (3%)
Unknown 3 (10%)
Disease stage at diagnosis
Ic 1 (3%)
II 1 (3%)
III 17 (59%)
IV 10 (34%)
Degree of differentiation at diagnosis
Moderate 7 (24%)
Poor 22 (76%)
Prior chemotherapy: number of courses
1 4 (14%)
2 13 (45%)
42 12 (41%)
Treatment-free interval
46 months 8 (28%)
o6 months 21 (72%)
Prior platinum chemotherapy: best response
Complete/partial response 20 (70%)
Stable disease 3 (10%)
Progressive disease 0
Not evaluable/unknown 6 (21%)
Platinum-free interval
46 months 20 (70%)
o6 months 9 (30%)
NB¼no patients had received 5-FU previously.
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mild alopecia. The only grade 4 adverse event was uncomplicated
leucopenia, which occurred in one patient. There were no
treatment-related deaths during the study.
Health-related QOL
The number of patients evaluable for QOL in each cycle was as
follows: 29 (cycle 1); 28 (cycle 2); 23 (cycle 3); 18 (cycle 4); 12 (cycle
5); 5 (cycle 6). Of the 29 patients, 28 (97%) evaluable for QOL
completed their questionnaires prior to cycle 1 and 75 80% of
patients completed questionnaires prior to cycles 2 6.
When averaged over available assessments, mean change in QOL
scores from baseline indicated a significant decline in physical
function together with an increase in levels of fatigue during the
course of chemotherapy (P¼0.021 and 0.049, respectively). There
was a trend towards significant reduction in role function
(P¼0.054), but in other domains of the questionnaire, no
significant decreases in averaged scores were noted.
DISCUSSION
Capecitabine is an active agent for the treatment of patients with
ovarian cancer previously treated with platinum and taxanes.
Using CA125 concentrations to indicate response, capecitabine
−20 20 60 100 140 180
Time (days)
−20 20 60 100 140 180
Time (days)
10000
1000
100
10
C
A
1
2
5
 
(
k
U
 
L
−
1
)
10000
1000
100
10
C
A
1
2
5
 
(
k
U
 
L
−
1
)
A
B
Figure 1 Typical responder profiles (CA125 response curves).
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Figure 2 Progression-free survival.
1.0
0.8
0.6
0.4
0.2
0.0
E
s
t
i
m
a
t
e
d
 
p
r
o
b
a
b
i
l
i
t
y
0 61 21 824 30
Time (months)
8.0
Figure 3 Overall survival.
Table 3 Most common (X10%) treatment-related adverse events, all
grades (n¼29)
All grades Grade 3 Grade 4
Adverse event No (%) No (%) No (%)
Anaemia 23 (79) 1 (3) 0
Hand–foot syndrome 18 (62) 4 (14) 0
Nausea 17 (59) 1 (3) 0
Diarrhoea 17 (59) 2 (7) 0
Vomiting 14 (48) 3 (10) 0
Leucopenia 13 (45) 0 1 (3)
Fatigue 12 (41) 1 (3) 0
Neutropenia 9 (31) 1 (3) 0
Stomatitis 9 (31) 0 0
Thrombocytopenia 8 (28) 0 0
Constipation 6 (21) 0 0
Anorexia 3 (10) 1 (3) 0
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lresulted in a response rate of 29% in a population of 28 evaluable
patients. Capecitabine also demonstrated a favourable and
manageable safety profile in this trial, with a particularly low rate
of myelosuppression and alopecia. The most common grade 3
clinical adverse event was the cutaneous disorder HFS, which is
never directly life-threatening and is readily managed using dose
modification and/or treatment interruption. Grade 3 HFS occurred
in 14% of patients and 10% experienced grade 3 vomiting. A
similar safety profile was observed during extensive phase II and
III trials of capecitabine in MBC and metastatic colorectal cancer
(Cassidy et al, 2002; O’Shaughnessy, 2002). The only previous
experience with this agent in recurrent ovarian cancer demon-
strated a clinical response rate of 25% (one complete response and
two partial responses in 12 evaluable patients) using the same
doses but administered on a 28-day schedule (Boehmer and Jaeger,
2002).
The interpretation of the CA125 response in patients who have
undergone ascitic drainage is difficult. There are a number of
different strategies that may be employed in this situation,
including the exclusion from the analysis of all patients who have
had ascites drained, or using predetermined criteria based on the
frequency of evaluable CA125 measurements during treatment. In
our study, three of the eight patients with the CA125 response had
required drainage of ascites. In one patient, ascitic drainage was
performed after observation of CA125 response, but in the
remaining two patients, one of whom had two drainage procedures
performed, three of 14 and six of 10 of their CA125 values were
taken within 4 weeks of drainage of ascites. Following exclusion of
these values, neither patient would be considered to be a
responder, despite clearly showing clinical benefit from capecita-
bine treatment. Further investigation of the effect of ascitic
drainage on interpretation of the CA125 response dynamics is
required.
The intrinsic variability of CA125 estimations needs to be
addressed, particularly with reference to the frequency of
sampling. This is particularly relevant in this study, because the
one patient with measurable disease who had a clinical response
could not be classified as a CA125 responder. A single weekly
CA125 value was 410% higher than the previous result, and
therefore that patient is not classified as responding despite having
a sustained 450% reduction from baseline.
As CA125 sampling is far less expensive than multiple CT
scanning, it may lead to great cost savings for health-care systems.
Many patients with relapsed ovarian cancer do not have clinically
or radiologically measurable disease, and the use of CA125
response as the primary outcome measure consequently allows
the inclusion of more patients in clinical trials. Providing patients
have an initial CA125 concentration that is high enough to observe
the requisite 50% fall, more patients will be eligible for entry into
such trials.
The efficacy and safety of capecitabine in this setting compare
favourably with other available monotherapies, including topote-
can, paclitaxel and pegylated liposomal doxorubicin (PLD).
Although the numbers of patients in this study are small, there
is evidence that capecitabine is active against refractory tumours.
Large, randomised trials have compared topotecan with paclitaxel
or PLD in patients progressing after first-line platinum-based
therapy. In these studies, response rates of 17–20.5% for
topotecan, 13% for paclitaxel and 20% for PLD were observed
(ten Bokkel Huinink et al, 1997; Gordon et al, 2001). In our study,
a response rate of 29% was achieved in a relatively heavily
pretreated population of patients (median of two previous
chemotherapies). The median progression-free survival (3.7
months) achieved in our study is similar to those of topotecan
(3.7–5.3 months), paclitaxel (3.2 months) and PLD (3.7 months).
One of the main advantages of capecitabine over other
available therapies is its convenience and tolerability. In
contrast to agents such as topotecan and paclitaxel (ten
Bokkel Huinink et al, 1997), grade 3 neutropenia was rare, and
observed in only one patient during our study and there was
only one grade 4 event (leucopenia). In addition, alopecia occurred
in only one (3%) patient treated with capecitabine, at grade 1
intensity.
High attrition rates hinder the interpretation of the QOL data
collected during the study, in addition to the lack of an
observation-only comparator. Averaged scores showed a statisti-
cally significant decline in physical function and increase in fatigue
over the course of the study, but only one patient experienced
grade 3 fatigue. QOL scores in other domains, including social
function and body image, were not significantly reduced. More-
over, cognitive function, body image and attitude to disease/
treatment showed trends towards improved QOL. In other studies,
the addition of capecitabine to docetaxel significantly improved
survival without compromising quality of life in 255 patients
(Twelves et al, 2001). There is increasing evidence that patients’
judgements of their QOL are quite accurate and consistent
(Waldron et al, 1999); nevertheless, the sensitivity of the EORTC
questionnaires to the benefits of an oral treatment is not proven.
Ongoing studies of capecitabine are using convenience and
satisfaction questionnaires (FACIT) and will improve our under-
standing of the effect of patients’ values, preferences and life
priorities on treatment decisions.
The potential for capecitabine as the backbone of effective
combination regimens has been established in numerous studies in
breast, colorectal and gastrointestinal malignancies. In these
indications, capecitabine in combination with other cytotoxic
agents, including docetaxel, oxaliplatin and irinotecan, has
demonstrated high activity and an acceptable safety profile (Kerr
et al, 2002; O’Shaughnessy et al, 2002; Sastre et al, 2002). Although
combination regimens have yet to demonstrate benefits in efficacy
compared with single-agent therapy in randomised trials of
patients with relapsed ovarian cancer (Chi and Sabbatini, 2000),
this should not automatically preclude trials investigating new
combinations that may achieve an acceptable balance of efficacy
and tolerability. Indeed, the highest response rates in phase II
studies of platinum-resistant disease can be seen using dose-dense
combination regimens (Meyer et al, 2001; van der Burg et al, 2002).
The potential for capecitabine to be used in combination with
agents that upregulate thymidine phosphorylase in relapsed
ovarian cancer is clear.
In summary, capecitabine has demonstrated promising activity
and a favourable safety profile in the treatment of platinum-
refractory epithelial ovarian cancer. This agent is now being
investigated further in patients with relapsed ovarian cancer. The
safety and convenience advantages afforded to patients over
current i.v. options make capecitabine an ideal agent for
administration in the outpatient setting, potentially freeing them
from the burden of i.v. therapy.
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